Abstract:Introduction Lithium nephropathy can occur in long-term lithium-treated bipolar disorder patients. Key risk factors include duration of lithium exposure, cumulative dose, acute intoxication episodes, advanced age, and comorbidities such as hypertension, diabetes mellitus, hyperparathyroidism, and hyperuricemia, along with concurrent use of antipsychotics. The clinical presentation is gradual, with mild proteinuria, often accompanied by arginine vasopressin resistance. Histological studies show a correlation between interstitial fibrosis and cumulative lithium duration. Approximately 15 to 25 per cent of exposed patients may experience a gradual decline in glomerular filtration rate. The outcome after lithium discontinuation varies. Objectives This case study aims to analyze and document the clinical presentation, diagnosis, and management of lithium nephropathy in a patient with Bipolar Disorder. Methods We gathered data on the medical history, lab results, and treatment approach for a patient with Bipolar Disorder. Results The patient, a 50-year-old woman, had been under the care of Psychiatry since 2008 due to a diagnosis of Bipolar Disorder Type I. During this time, she had experienced depressive and manic episodes but had not presented significant symptom decompensation for the past 14 years, successfully managed with lithium at a current dose of 600 mg per day. However, on this occasion, the patient sought hospitalization due to recent behavioural disturbances, including restlessness, disinhibition, abrupt changes in behaviour, pressured speech, sleep problems, agitation, and aggression. The patient also reported an increased sense of polyuria and polydipsia. Evaluation in the emergency department revealed elevated lithium levels of 1.47 mmol/L and hypokalemia, that justified lithium withdrawal. After lithium levels decreased, an estimated glomerular filtration rate remained low. She was diagnosed with lithium nephropathy, an adverse effect of long-term lithium therapy. Treatment with lithium changed to sodium valproate. Treatment with asenapine started and sustained for two months. Over the following two years, the patient experienced four additional hospital admissions in Psychiatry due to manic episodes. Conclusions Long-term lithium therapy can lead to lithium nephropathy with symptoms such as polyuria, polydipsia, and acute kidney failure. Consistent monitoring of patients receiving lithium is crucial to detect potential adverse effects.This case highlights the challenges in managing bipolar patients, as discontinuing lithium exacerbated symptoms despite switching to sodium valproate for nephropathy prevention. Long-term lithium treatment, while effective for bipolar disorder, poses significant renal risks. We emphasize continuous renal function monitoring and assessing the risk-benefit of lithium treatment while actively researching lithium nephropathy and its impact on glomerular function. Disclosure of Interest None Declared

The Dilemma of Lithium Discontinuation in Bipolar Disorder During Pregnancy Planning: A Case Report and Literature Review

Olanzapine Versus Lithium in the Acute Treatment of Bipolar Mania: A Double-Blind, Randomized, Controlled Trial

Obstetric Outcomes in Women on Lithium: A Systematic Review and Meta-Analysis

A Case of Severe Polyhydramnios During Pregnancy Associated with Long-Term Use of Lithium

Retrospective Review of Postpartum Lithium Use Including During Lactation

A case of pregnancy with severe polyhydramnios related to long‐term use of lithium

Dose response relationship between lithium serum levels during pregnancy and birth outcomes

A patient with acute mania after discontinuation of lithium

Striking the Balance: Bipolar Disorder in the Perinatal Period

Lithium nephropathy in Bipolar Disorder: a clinical challenge

Expert advice on the management of valproate in women with bipolar disorder at childbearing age

Pharmacological treatment of bipolar disorder in pregnancy: An update on safety considerations

Lithium Use During Pregnancy in 14 Countries

Lithium Use During Pregnancy and the Risk of Miscarriage.

The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention

Navigating the Complexity of a Bipolar Pregnant Patient With Multiple Comorbidities

Epidemiology studies on effects of lithium salts in pregnancy are confounded by the inability to control for other potentially teratogenic factors

Clinical course and need for hospital admission after lithium discontinuation in patients with bipolar disorder type I or II: mirror-image study based on the LiSIE retrospective cohort

Lithium from breast-milk inhibits thyroid iodine uptake and hormone production, which are remedied by maternal iodine supplementation

Lithium-discontinuation-induced treatment refractoriness revisited

Reviewing the art of safe prescription practices: A checklist for the use of psychotropic drugs during pregnancy